Antigen-specific therapy, which we previously showed to delay diabetes development in pre-diabetic NOD mice (insB9–23/IFA) [23], was combined with an immunomodulatory treatment (G-CSF/RAPA) that we developed for controlling allograft rejection [36]. This evidence concerns the gene CSF3 and diabetes mellitus.